董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Anthony DiGiandomenico | 男 | Director | 57 | 4.10万美元 | 未持股 | 2025-11-28 |
| Michael Harsh | 男 | Director | 70 | 4.10万美元 | 未持股 | 2025-11-28 |
| Louis J. Basenese | 男 | Director | 47 | 4.10万美元 | 未持股 | 2025-11-28 |
| Alexander Tokman | 男 | Director,Chief Executive Officer and Chairman | 63 | 21.52万美元 | 未持股 | 2025-11-28 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Richard Jacroux | 男 | Chief Financial Officer | 58 | 9.59万美元 | 未持股 | 2025-11-28 |
| Alexander Tokman | 男 | Director,Chief Executive Officer and Chairman | 63 | 21.52万美元 | 未持股 | 2025-11-28 |
董事简历
中英对照 | 中文 | 英文- Anthony DiGiandomenico
-
Anthony DiGiandomenico，自公司于2021年8月10日成立以来，他一直担任New Venture Discovery的负责人和董事。2013年7月至今，他还担任增强超声技术开发商ENDRA Life Sciences Inc.（纳斯达克股票代码：NDRA）的董事会成员；2017年1月至2020年5月，担任多种药物治疗开发商Provention Bio， Inc.的董事会成员；从2016年1月至2019年10月，开发用于选择性调节人类免疫系统的新型生物药物，以治疗广泛的癌症和自身免疫性疾病。自1997年共同创立前身为MDB Capital Group， LLC的Public Ventures以来，DiGiandomenico先生一直致力于对早期颠覆性技术的投资。他曾与生物技术、医疗设备、高科技和可再生能源领域的众多公司合作。他持有加州大学伯克利分校哈斯商学院的工商管理硕士学位和Colorado大学的金融学士学位。
Anthony DiGiandomenico has been the Head of New Venture Discovery and director since the inception of the Company on Augt 10,2021. Mr. DiGiandomenico serves as a board of director to eXoZymes, Inc and ClearSign, Inc. He has also served on the board of directors of ENDRA Life Sciences Inc. (Nasdaq: NDRA), a developer of enhanced ultrasound technology, from July 2013 until present, the board of directors of Provention Bio, Inc., a developer of multiple drug therapies, from January 2017 until May 2020 and the board of directors of Cue Biopharma, Inc., that develops novel biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders from January 2016 to October 2019. Since he co founded Public Ventures (formerly known as MDB Capital Group, LLC) in 1997, Mr. DiGiandomenico has been enabling investment into early stage disruptive technologies. He has worked alongside a wide range of companies in biotechnology, medical devices, high technology, and renewable energy spaces. Mr. DiGiandomenico holds an MBA from the Haas School of Biness at the University of California, Berkeley and a BS in Finance from the University of Colorado. Mr. DiGiandomenico's financial expertise, general biness acumen and significant executive leadership experience position him ll to make valuable contributions to board of directors. - Anthony DiGiandomenico，自公司于2021年8月10日成立以来，他一直担任New Venture Discovery的负责人和董事。2013年7月至今，他还担任增强超声技术开发商ENDRA Life Sciences Inc.（纳斯达克股票代码：NDRA）的董事会成员；2017年1月至2020年5月，担任多种药物治疗开发商Provention Bio， Inc.的董事会成员；从2016年1月至2019年10月，开发用于选择性调节人类免疫系统的新型生物药物，以治疗广泛的癌症和自身免疫性疾病。自1997年共同创立前身为MDB Capital Group， LLC的Public Ventures以来，DiGiandomenico先生一直致力于对早期颠覆性技术的投资。他曾与生物技术、医疗设备、高科技和可再生能源领域的众多公司合作。他持有加州大学伯克利分校哈斯商学院的工商管理硕士学位和Colorado大学的金融学士学位。
- Anthony DiGiandomenico has been the Head of New Venture Discovery and director since the inception of the Company on Augt 10,2021. Mr. DiGiandomenico serves as a board of director to eXoZymes, Inc and ClearSign, Inc. He has also served on the board of directors of ENDRA Life Sciences Inc. (Nasdaq: NDRA), a developer of enhanced ultrasound technology, from July 2013 until present, the board of directors of Provention Bio, Inc., a developer of multiple drug therapies, from January 2017 until May 2020 and the board of directors of Cue Biopharma, Inc., that develops novel biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders from January 2016 to October 2019. Since he co founded Public Ventures (formerly known as MDB Capital Group, LLC) in 1997, Mr. DiGiandomenico has been enabling investment into early stage disruptive technologies. He has worked alongside a wide range of companies in biotechnology, medical devices, high technology, and renewable energy spaces. Mr. DiGiandomenico holds an MBA from the Haas School of Biness at the University of California, Berkeley and a BS in Finance from the University of Colorado. Mr. DiGiandomenico's financial expertise, general biness acumen and significant executive leadership experience position him ll to make valuable contributions to board of directors.
- Michael Harsh
-
Michael Harsh，他于2015年加入ENDRA公司的董事会。他拥有36年的医疗技术的经验，专注于诊断成像。他最近担任GE Healthcare公司的副总裁兼首席技术官，并领导其全球科技组织和研发团队，涉及诊断、医疗保健和生命科学。他于2004年被任命为the GE Global Research Center的全球技术领导者，负责成像技术实验室，在那里他领导公司成像技术的研究，以及计算机视觉/图像分析和超导系统相关的研究。他领导GE Industrial and Enterprise Solutions的工程部门（2006年至2009年）。他于2006年11月被任命为General Electric Company的职员。他是Terapede Systems Inc.（数字x射线探测器初创公司）的联席创始人兼现任首席产品官、FloDesign Sonics, Inc.的董事会成员、Phoenix Nuclear Labs, LLC的科学顾问委员会成员，以及医疗设备行业的初创公司的顾问。他毕业于Marquette University， 在那里他获得电气工程学士学位。他持有多个医学成像和仪表领域的美国专利。他于2008年入选the American Institute for Medical and Biological Engineering College of Fellows，是因为他在医学和生物工程领域的重大贡献。
Michael Harsh joined Board of Directors in 2015. He is a Portfolio Executive for the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) COVID 19 Response Program and a co founder and Chief Product Officer of Terapede Systems, a digital Xray startup that foces on developing an ultra high resolution medical flat panel X ray detector. He co founded Terapede in 2015. Prior to Terapede, Mr. Harsh had a 36 year career with General Electric ("GE"). He held numero positions within GE and served as Vice President and Chief Technology Officer of GE Healthcare, a multi billion dollar division of GE, where he led its global science and technology organization and research and development teams in diagnostics, healthcare IT and life sciences. In 2004, Mr. Harsh was named Global Technology Leader Imaging Technologies at the GE Global Research Center, where he led the research for imaging technologies across the company as ll as the research associated with computer visualization and superconducting systems. Additionally, Mr. Harsh is a member of the boards of directors of Compute Health (NYSE: CPUH UN), Imagion Biosystems (IBX.AX), and EmOpti, as ll as a member of the Radiological Society of North America (RSNA), Research & Education Foundation Board of Trtees. He had previoly served as a director for FloDesign Sonics until its acquisition by MilliporeSigma, a division of the Merck Group. He is also a McKinsey Senior Advisor and a consultant in the medical device indtry.Mr. Harsh is a graduate of Marquette University, where he earned a bachelor's degree in Electrical Engineering. He holds numero U.S. patents in the field of medical imaging and instrumentation. In 2008, Mr. Harsh was elected to the American Institute for Medical and Biological Engineering College of Fellows for his significant contributions to the medical and biological engineering field. - Michael Harsh，他于2015年加入ENDRA公司的董事会。他拥有36年的医疗技术的经验，专注于诊断成像。他最近担任GE Healthcare公司的副总裁兼首席技术官，并领导其全球科技组织和研发团队，涉及诊断、医疗保健和生命科学。他于2004年被任命为the GE Global Research Center的全球技术领导者，负责成像技术实验室，在那里他领导公司成像技术的研究，以及计算机视觉/图像分析和超导系统相关的研究。他领导GE Industrial and Enterprise Solutions的工程部门（2006年至2009年）。他于2006年11月被任命为General Electric Company的职员。他是Terapede Systems Inc.（数字x射线探测器初创公司）的联席创始人兼现任首席产品官、FloDesign Sonics, Inc.的董事会成员、Phoenix Nuclear Labs, LLC的科学顾问委员会成员，以及医疗设备行业的初创公司的顾问。他毕业于Marquette University， 在那里他获得电气工程学士学位。他持有多个医学成像和仪表领域的美国专利。他于2008年入选the American Institute for Medical and Biological Engineering College of Fellows，是因为他在医学和生物工程领域的重大贡献。
- Michael Harsh joined Board of Directors in 2015. He is a Portfolio Executive for the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) COVID 19 Response Program and a co founder and Chief Product Officer of Terapede Systems, a digital Xray startup that foces on developing an ultra high resolution medical flat panel X ray detector. He co founded Terapede in 2015. Prior to Terapede, Mr. Harsh had a 36 year career with General Electric ("GE"). He held numero positions within GE and served as Vice President and Chief Technology Officer of GE Healthcare, a multi billion dollar division of GE, where he led its global science and technology organization and research and development teams in diagnostics, healthcare IT and life sciences. In 2004, Mr. Harsh was named Global Technology Leader Imaging Technologies at the GE Global Research Center, where he led the research for imaging technologies across the company as ll as the research associated with computer visualization and superconducting systems. Additionally, Mr. Harsh is a member of the boards of directors of Compute Health (NYSE: CPUH UN), Imagion Biosystems (IBX.AX), and EmOpti, as ll as a member of the Radiological Society of North America (RSNA), Research & Education Foundation Board of Trtees. He had previoly served as a director for FloDesign Sonics until its acquisition by MilliporeSigma, a division of the Merck Group. He is also a McKinsey Senior Advisor and a consultant in the medical device indtry.Mr. Harsh is a graduate of Marquette University, where he earned a bachelor's degree in Electrical Engineering. He holds numero U.S. patents in the field of medical imaging and instrumentation. In 2008, Mr. Harsh was elected to the American Institute for Medical and Biological Engineering College of Fellows for his significant contributions to the medical and biological engineering field.
- Louis J. Basenese
-
Louis J.Basenese于2020年4月加入我们的董事会。Basenese先生是Disruptive Tech Research，LLC的创始人兼首席分析师，该公司是一家独立的股票研究和咨询公司，自2014年6月以来一直专注于服务于投资管理社区的破坏性技术公司。自2005年以来，Basenese先生还管理The Basenese Group，LLC，该公司是一家咨询公司，专注于私人和公共小型和微型企业的通信和业务发展。Basenese先生拥有罗林斯学院克拉默商学院（Crummer Graduate School of Business at Rollins College）的金融工商管理硕士学位和佛罗里达大学（University of Florida）的文学学士学位。
Louis J. Basenese joined Board of Directors in April 2020. As of January 2025, Mr. Basenese is the Executive Vice President Market Strategy at Prairie Operating Corp. Mr. Basenese has served on the board of ClearSign Technologies Corporation (Nasdaq: NCLIR) since May 22, 2025. Prior to that, Mr. Basenese served as President, Chief Market Strategist at Public Ventures, LLC (dba MDB Capital), a registered broker dealer, Member FINRA/SIPC, from June 2022 to January 2025. Previoly, he was Founder and Chief Analyst of Disruptive Tech Research, LLC, an independent equity research and advisory firm foced exclively on disruptive technology companies that has served the investment management community from June 2014 through September 2022. Since 2005, Mr. Basenese has also managed The Basenese Group, LLC, a consulting biness foced on communications and biness development for private and public small and microcap binesses.Mr. Basenese holds an M.B.A. in Finance from the Crummer Graduate School of Biness at Rollins College and a Bachelor of Arts from the University of Florida. He is also a former Series 7 and Series 66 license holder. - Louis J.Basenese于2020年4月加入我们的董事会。Basenese先生是Disruptive Tech Research，LLC的创始人兼首席分析师，该公司是一家独立的股票研究和咨询公司，自2014年6月以来一直专注于服务于投资管理社区的破坏性技术公司。自2005年以来，Basenese先生还管理The Basenese Group，LLC，该公司是一家咨询公司，专注于私人和公共小型和微型企业的通信和业务发展。Basenese先生拥有罗林斯学院克拉默商学院（Crummer Graduate School of Business at Rollins College）的金融工商管理硕士学位和佛罗里达大学（University of Florida）的文学学士学位。
- Louis J. Basenese joined Board of Directors in April 2020. As of January 2025, Mr. Basenese is the Executive Vice President Market Strategy at Prairie Operating Corp. Mr. Basenese has served on the board of ClearSign Technologies Corporation (Nasdaq: NCLIR) since May 22, 2025. Prior to that, Mr. Basenese served as President, Chief Market Strategist at Public Ventures, LLC (dba MDB Capital), a registered broker dealer, Member FINRA/SIPC, from June 2022 to January 2025. Previoly, he was Founder and Chief Analyst of Disruptive Tech Research, LLC, an independent equity research and advisory firm foced exclively on disruptive technology companies that has served the investment management community from June 2014 through September 2022. Since 2005, Mr. Basenese has also managed The Basenese Group, LLC, a consulting biness foced on communications and biness development for private and public small and microcap binesses.Mr. Basenese holds an M.B.A. in Finance from the Crummer Graduate School of Biness at Rollins College and a Bachelor of Arts from the University of Florida. He is also a former Series 7 and Series 66 license holder.
- Alexander Tokman
-
Alexander Tokman ，他曾担任MicroVision公司的总裁、首席执行官和董事（自2006年1月以来）。他曾担任MicroVision公司的总裁兼首席营运官（从2005年7月到2006年1月）。他是前任通用电气（GE）高管，并在任职通用电气医疗集团（GE Healthcare）（General Electric公司的子公司）10年后加入MicroVision公司，在那里他领导几个全球业务，最近作为其全球分子成像和放射性药物学多元技术业务部门总经理（从2003年到2005年）。从1995年到2003年，他担任GE公司的各种跨职能和跨企业的领导职务，领导了包括PET / CT的几个医学模式产品领域的定义和商业化，促进了超过5亿美元的营收增长（来自于该公司前三年的商业介绍）。他是注册Six Sigma，Six Sigma DFSS Black Belt的设计师和六西格玛黑带大师，也是通用电气公司的六西格玛先锋，并于1990年代后期在通用电气医疗集团进行了质量文化变革。从1989年11月到1989年3月，他担任 Tracor Applied Sciences公司（Tracor公司的子公司）的新技术项目领导和I&RD办公室主管。他持有马萨诸塞达特茅斯大学（University of Massachusetts）的电气工程硕士学位。
Alexander Tokman,joined Endra Life Sciences Inc. Board of Directors in 2008. He currently serves as a President of iUNU, a privately held AI/Computer Vision SaaS company and recently was a CEO-in-Residence at the Allen Institute for Artificial Intelligence (AI2), from 2019 to 2020. Mr. Tokman also serves as an independent board director for Izotropic Corporation (CSE: IZO), a company commercializing a dedicated breast CT imaging platform, and on the board of the American Academy of Thermography, a non-profit organization focused on bringing novel infrared imaging applications for disease diagnosis.Mr. Tokman served as President, Chief Executive Officer, and a director of Microvision, Inc., a publicly traded laser beam scanning display and imaging company, from January 2006 to December 2017.Previously, Mr. Tokman completed a 10+ year tenure as an executive with GE Healthcare, where he led several global businesses, the latest being its Global Molecular Imaging and Radiopharmacy multi-technology business unit, of which he was General Manager from 2003 to 2005.Between 1995 and 2003, Mr. Tokman served in various leadership roles at GE Healthcare, where he led the definition and successful commercialization of several product segments, including PET/CT.Mr. Tokman is a certified Six Sigma and Design for Six Sigma (DFSS) Black Belt and Master Black Belt and as one of General Electric Company's Six Sigma pioneers, he drove the quality culture change across GE Healthcare in the late 1990s. From 1989 to 1995, Mr. Tokman served as development programs lead and a head of Industry and Regional Development at Tracor Applied Sciences (BAE Systems). Mr. Tokman has both an MS and BS in Electrical Engineering from the University of Massachusetts, Dartmouth. - Alexander Tokman ，他曾担任MicroVision公司的总裁、首席执行官和董事（自2006年1月以来）。他曾担任MicroVision公司的总裁兼首席营运官（从2005年7月到2006年1月）。他是前任通用电气（GE）高管，并在任职通用电气医疗集团（GE Healthcare）（General Electric公司的子公司）10年后加入MicroVision公司，在那里他领导几个全球业务，最近作为其全球分子成像和放射性药物学多元技术业务部门总经理（从2003年到2005年）。从1995年到2003年，他担任GE公司的各种跨职能和跨企业的领导职务，领导了包括PET / CT的几个医学模式产品领域的定义和商业化，促进了超过5亿美元的营收增长（来自于该公司前三年的商业介绍）。他是注册Six Sigma，Six Sigma DFSS Black Belt的设计师和六西格玛黑带大师，也是通用电气公司的六西格玛先锋，并于1990年代后期在通用电气医疗集团进行了质量文化变革。从1989年11月到1989年3月，他担任 Tracor Applied Sciences公司（Tracor公司的子公司）的新技术项目领导和I&RD办公室主管。他持有马萨诸塞达特茅斯大学（University of Massachusetts）的电气工程硕士学位。
- Alexander Tokman,joined Endra Life Sciences Inc. Board of Directors in 2008. He currently serves as a President of iUNU, a privately held AI/Computer Vision SaaS company and recently was a CEO-in-Residence at the Allen Institute for Artificial Intelligence (AI2), from 2019 to 2020. Mr. Tokman also serves as an independent board director for Izotropic Corporation (CSE: IZO), a company commercializing a dedicated breast CT imaging platform, and on the board of the American Academy of Thermography, a non-profit organization focused on bringing novel infrared imaging applications for disease diagnosis.Mr. Tokman served as President, Chief Executive Officer, and a director of Microvision, Inc., a publicly traded laser beam scanning display and imaging company, from January 2006 to December 2017.Previously, Mr. Tokman completed a 10+ year tenure as an executive with GE Healthcare, where he led several global businesses, the latest being its Global Molecular Imaging and Radiopharmacy multi-technology business unit, of which he was General Manager from 2003 to 2005.Between 1995 and 2003, Mr. Tokman served in various leadership roles at GE Healthcare, where he led the definition and successful commercialization of several product segments, including PET/CT.Mr. Tokman is a certified Six Sigma and Design for Six Sigma (DFSS) Black Belt and Master Black Belt and as one of General Electric Company's Six Sigma pioneers, he drove the quality culture change across GE Healthcare in the late 1990s. From 1989 to 1995, Mr. Tokman served as development programs lead and a head of Industry and Regional Development at Tracor Applied Sciences (BAE Systems). Mr. Tokman has both an MS and BS in Electrical Engineering from the University of Massachusetts, Dartmouth.
高管简历
中英对照 | 中文 | 英文- Richard Jacroux
Richard Jacroux于2024年8月7日被董事会任命为首席财务官，担任公司首席财务官兼首席会计官。Jacroux先生在财务管理和会计方面拥有超过20年的经验，并在安永会计师事务所开始了他的职业生涯。在加入ENDRA之前，Jacroux先生曾担任IUNU，Inc.和Buddy Platform，LTD的首席财务官。2023年，他创立了Impact Solve，LLC（dBA Impact Solutions），这是一家会计和零碎首席财务官服务公司。他还曾在华盛顿大学担任兼职教授超过5年。Jacroux先生获得华盛顿大学BINCE行政管理和会计学士学位，以及家乐氏管理学院MBA学位。
Richard Jacroux was appointed Chief Financial Officer by the Board on Augt 7, 2024, and serves as Principal Financial Officer and Principal Accounting Officer for the Company. Mr. Jacroux has over 20 years of experience in financial management and accounting and began his career at Ernst & Young LLP. Prior to ENDRA, Mr Jacroux served as Chief Financial Officer of IUNU, Inc. and Buddy Platform, LTD. In 2023 he founded Impact Solve, LLC (dba Impact Solutions), an accounting and fractional chief financial officer service firm. He has also served as an adjunct professor at the University of Washington for more than 5 years. Mr. Jacroux received a BA in biness administration and accounting from the University of Washington, and an MBA from the Kellogg School of Management.- Richard Jacroux于2024年8月7日被董事会任命为首席财务官，担任公司首席财务官兼首席会计官。Jacroux先生在财务管理和会计方面拥有超过20年的经验，并在安永会计师事务所开始了他的职业生涯。在加入ENDRA之前，Jacroux先生曾担任IUNU，Inc.和Buddy Platform，LTD的首席财务官。2023年，他创立了Impact Solve，LLC（dBA Impact Solutions），这是一家会计和零碎首席财务官服务公司。他还曾在华盛顿大学担任兼职教授超过5年。Jacroux先生获得华盛顿大学BINCE行政管理和会计学士学位，以及家乐氏管理学院MBA学位。
- Richard Jacroux was appointed Chief Financial Officer by the Board on Augt 7, 2024, and serves as Principal Financial Officer and Principal Accounting Officer for the Company. Mr. Jacroux has over 20 years of experience in financial management and accounting and began his career at Ernst & Young LLP. Prior to ENDRA, Mr Jacroux served as Chief Financial Officer of IUNU, Inc. and Buddy Platform, LTD. In 2023 he founded Impact Solve, LLC (dba Impact Solutions), an accounting and fractional chief financial officer service firm. He has also served as an adjunct professor at the University of Washington for more than 5 years. Mr. Jacroux received a BA in biness administration and accounting from the University of Washington, and an MBA from the Kellogg School of Management.
- Alexander Tokman
Alexander Tokman ，他曾担任MicroVision公司的总裁、首席执行官和董事（自2006年1月以来）。他曾担任MicroVision公司的总裁兼首席营运官（从2005年7月到2006年1月）。他是前任通用电气（GE）高管，并在任职通用电气医疗集团（GE Healthcare）（General Electric公司的子公司）10年后加入MicroVision公司，在那里他领导几个全球业务，最近作为其全球分子成像和放射性药物学多元技术业务部门总经理（从2003年到2005年）。从1995年到2003年，他担任GE公司的各种跨职能和跨企业的领导职务，领导了包括PET / CT的几个医学模式产品领域的定义和商业化，促进了超过5亿美元的营收增长（来自于该公司前三年的商业介绍）。他是注册Six Sigma，Six Sigma DFSS Black Belt的设计师和六西格玛黑带大师，也是通用电气公司的六西格玛先锋，并于1990年代后期在通用电气医疗集团进行了质量文化变革。从1989年11月到1989年3月，他担任 Tracor Applied Sciences公司（Tracor公司的子公司）的新技术项目领导和I&RD办公室主管。他持有马萨诸塞达特茅斯大学（University of Massachusetts）的电气工程硕士学位。
Alexander Tokman,joined Endra Life Sciences Inc. Board of Directors in 2008. He currently serves as a President of iUNU, a privately held AI/Computer Vision SaaS company and recently was a CEO-in-Residence at the Allen Institute for Artificial Intelligence (AI2), from 2019 to 2020. Mr. Tokman also serves as an independent board director for Izotropic Corporation (CSE: IZO), a company commercializing a dedicated breast CT imaging platform, and on the board of the American Academy of Thermography, a non-profit organization focused on bringing novel infrared imaging applications for disease diagnosis.Mr. Tokman served as President, Chief Executive Officer, and a director of Microvision, Inc., a publicly traded laser beam scanning display and imaging company, from January 2006 to December 2017.Previously, Mr. Tokman completed a 10+ year tenure as an executive with GE Healthcare, where he led several global businesses, the latest being its Global Molecular Imaging and Radiopharmacy multi-technology business unit, of which he was General Manager from 2003 to 2005.Between 1995 and 2003, Mr. Tokman served in various leadership roles at GE Healthcare, where he led the definition and successful commercialization of several product segments, including PET/CT.Mr. Tokman is a certified Six Sigma and Design for Six Sigma (DFSS) Black Belt and Master Black Belt and as one of General Electric Company's Six Sigma pioneers, he drove the quality culture change across GE Healthcare in the late 1990s. From 1989 to 1995, Mr. Tokman served as development programs lead and a head of Industry and Regional Development at Tracor Applied Sciences (BAE Systems). Mr. Tokman has both an MS and BS in Electrical Engineering from the University of Massachusetts, Dartmouth.- Alexander Tokman ，他曾担任MicroVision公司的总裁、首席执行官和董事（自2006年1月以来）。他曾担任MicroVision公司的总裁兼首席营运官（从2005年7月到2006年1月）。他是前任通用电气（GE）高管，并在任职通用电气医疗集团（GE Healthcare）（General Electric公司的子公司）10年后加入MicroVision公司，在那里他领导几个全球业务，最近作为其全球分子成像和放射性药物学多元技术业务部门总经理（从2003年到2005年）。从1995年到2003年，他担任GE公司的各种跨职能和跨企业的领导职务，领导了包括PET / CT的几个医学模式产品领域的定义和商业化，促进了超过5亿美元的营收增长（来自于该公司前三年的商业介绍）。他是注册Six Sigma，Six Sigma DFSS Black Belt的设计师和六西格玛黑带大师，也是通用电气公司的六西格玛先锋，并于1990年代后期在通用电气医疗集团进行了质量文化变革。从1989年11月到1989年3月，他担任 Tracor Applied Sciences公司（Tracor公司的子公司）的新技术项目领导和I&RD办公室主管。他持有马萨诸塞达特茅斯大学（University of Massachusetts）的电气工程硕士学位。
- Alexander Tokman,joined Endra Life Sciences Inc. Board of Directors in 2008. He currently serves as a President of iUNU, a privately held AI/Computer Vision SaaS company and recently was a CEO-in-Residence at the Allen Institute for Artificial Intelligence (AI2), from 2019 to 2020. Mr. Tokman also serves as an independent board director for Izotropic Corporation (CSE: IZO), a company commercializing a dedicated breast CT imaging platform, and on the board of the American Academy of Thermography, a non-profit organization focused on bringing novel infrared imaging applications for disease diagnosis.Mr. Tokman served as President, Chief Executive Officer, and a director of Microvision, Inc., a publicly traded laser beam scanning display and imaging company, from January 2006 to December 2017.Previously, Mr. Tokman completed a 10+ year tenure as an executive with GE Healthcare, where he led several global businesses, the latest being its Global Molecular Imaging and Radiopharmacy multi-technology business unit, of which he was General Manager from 2003 to 2005.Between 1995 and 2003, Mr. Tokman served in various leadership roles at GE Healthcare, where he led the definition and successful commercialization of several product segments, including PET/CT.Mr. Tokman is a certified Six Sigma and Design for Six Sigma (DFSS) Black Belt and Master Black Belt and as one of General Electric Company's Six Sigma pioneers, he drove the quality culture change across GE Healthcare in the late 1990s. From 1989 to 1995, Mr. Tokman served as development programs lead and a head of Industry and Regional Development at Tracor Applied Sciences (BAE Systems). Mr. Tokman has both an MS and BS in Electrical Engineering from the University of Massachusetts, Dartmouth.